4D Molecular Therapeutics develops gene therapies built on its Therapeutic Vector Evolution platform, which engineers customized adeno-associated virus (AAV) vectors. Programs target diseases of the eye, heart, and lung, aiming for more tissue-selective delivery than conventional AAV approaches. The company is primarily clinical-stage, with value driven by its vector technology and therapeutic pipeline rather than commercial product sales.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -54.7 | — |
| Q3 2025 | 0.1 | — | -56.9 | — |
| Q4 2025 | 85.1 | — | 19.4 | — |
| Q1 2026 | 3 | — | -68.8 | — |
| Q2 2026 | 3.8 | 25,106.7% | -72.9 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Midland States Bancorp, Inc. (MSBI), Petco Health and Wellness Company, Inc. (WOOF), OmniAb, Inc. (OABI), Red River Bancshares, Inc. (RRBI), Canadian Solar Inc. (CSIQ), Park-Ohio Holdings Corp. (PKOH)